"Leaky gut" is simultaneously one of the most overused terms in wellness culture and one of the most legitimate concepts in modern gastroenterology research. The problem is that two very different things share the same name. Intestinal permeability — the measurable passage of molecules through the gut lining — is a well-documented, physiologically real phenomenon studied in peer-reviewed journals for decades. "Leaky gut syndrome" — the idea that increased permeability is the root cause of everything from autoimmune disease to depression to chronic fatigue — is a significant overreach of what the evidence currently supports.
This guide separates the two. You will come away understanding the biology of the gut barrier, which conditions genuinely involve disrupted permeability, what the tests can and cannot tell you, and which interventions have actual human evidence behind them.
The intestinal lining is, in some respects, the most extraordinary organ in the body. It spans roughly 400 square meters of surface area — formed by millions of finger-like villi and microvilli — yet it is composed of a single layer of epithelial cells. This monolayer must simultaneously accomplish two opposing tasks: absorb nutrients efficiently and block pathogens, toxins, and undigested food particles from entering the bloodstream.
Layer 1 — The mucus layer. The outermost protective layer consists of mucus secreted by goblet cells, primarily made of mucin glycoproteins. The colon has two distinct mucus sublayers: a dense inner layer that bacteria cannot penetrate and a looser outer layer that hosts commensal microbiota. Akkermansia muciniphila, a keystone species that degrades mucins, paradoxically stimulates mucus production as a feedback mechanism — low Akkermansia is associated with a thinner mucus layer.
Layer 2 — The epithelial cell layer. Enterocytes (absorptive cells) cover approximately 90% of the gut surface. Their apical membranes are coated in a glycocalyx — a dense carbohydrate brush that adds another physical barrier. Between enterocytes, the tight junction complex seals the paracellular space (the gaps between cells).
Layer 3 — Tight junctions. This is where the leaky gut story is most grounded in molecular biology. Tight junctions are multiprotein complexes that stitch neighboring enterocytes together. The key structural proteins include:
When these junctions are intact and well-regulated, they permit a highly selective passage of water and small molecules. When they are disrupted — by inflammation, toxins, certain dietary components, or pathogens — the paracellular space opens and larger, immunogenic molecules gain access to the lamina propria and, eventually, systemic circulation.
There are two routes across the intestinal epithelium: transcellular (through the cell, tightly regulated) and paracellular (between cells, governed by tight junctions). "Leaky gut" refers to excessive paracellular permeability. This distinction matters because nutrients are primarily absorbed transcellularly — increased permeability is not the same as "absorbing more nutrients."
Not all molecular transit across the intestinal wall is pathological — some paracellular flux is normal and necessary for immune surveillance. The concern arises when the tight junction barrier breaks down enough to allow passage of two categories of problematic molecules.
LPS is a structural component of the outer membrane of gram-negative bacteria. It is essentially unavoidable in the gut lumen — your colon contains trillions of gram-negative bacteria. Under normal conditions, LPS is largely contained within the intestinal lumen, and small amounts that do enter the portal circulation are rapidly cleared by the liver.
When gut permeability increases, LPS translocation into systemic circulation rises. This triggers a well-characterized inflammatory cascade: LPS binds to Toll-Like Receptor 4 (TLR4) on macrophages and endothelial cells, activating NF-κB signaling and driving production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. This state — called metabolic endotoxemia — was first described by Cani et al. in a landmark 2007 paper in Diabetes, showing that a high-fat diet in mice raised plasma LPS 2–3 fold and induced adipose tissue inflammation.
Metabolic endotoxemia is now recognized as a potential mechanism linking gut dysbiosis and poor diet to systemic low-grade inflammation observed in obesity, type 2 diabetes, and non-alcoholic fatty liver disease. The causal direction in humans, however, is still being established.
The immune system in the gut mucosa must distinguish between harmless dietary antigens and genuine threats. This tolerance is partially maintained by the tight junction barrier — which limits the size and quantity of food proteins reaching the lamina propria. When permeability increases, larger peptide fragments gain access to mucosal immune cells (dendritic cells, macrophages, mast cells), potentially driving inappropriate immune responses. This is thought to be especially relevant in celiac disease, where gliadin peptides escape into the lamina propria and trigger an adaptive immune response in genetically susceptible individuals.
In 2000, gastroenterologist Alessio Fasano and colleagues at the University of Maryland discovered a molecule that directly regulates tight junction opening. They named it zonulin. The discovery emerged from research on cholera toxin — Fasano noticed that Vibrio cholerae triggered intestinal permeability through a receptor-mediated mechanism, leading to identification of an endogenous equivalent.
Zonulin is now understood to be identical to complement C3b and its precursor, with prehaptoglobin-2 also identified as a zonulin family member. It acts on the epidermal growth factor receptor (EGFR) and PAR2 (protease-activated receptor 2), triggering a Myosin Light Chain Kinase (MLCK) cascade that causes actin cytoskeleton rearrangement and ZO-1 internalization — physically pulling tight junctions open.
The clearest human model of zonulin-mediated permeability is celiac disease. Fasano's group demonstrated that gliadin (the protein fraction of gluten) binds to the CXCR3 chemokine receptor on enterocytes and triggers zonulin release — regardless of whether the individual has celiac disease, though the downstream immune response differs dramatically between celiacs and healthy controls.
In celiac disease, increased intestinal permeability is not merely an epiphenomenon — it is a causal step in the disease process. Zonulin opens tight junctions → gliadin peptides enter the lamina propria → tissue transglutaminase (tTG) modifies gliadin → HLA-DQ2/DQ8 presents modified peptides to T cells → CD4+ T cell activation → villous atrophy and crypt hyperplasia. This is the strongest mechanistic chain linking permeability to a specific disease, with multiple intervention studies showing that strict gluten removal normalizes both permeability and mucosal architecture.
Fasano et al. (2000), J Clin Invest: First characterization of zonulin as an endogenous tight junction regulator. Followed by Fasano (2012), Clinical Reviews in Allergy & Immunology — the most-cited review proposing that increased permeability is a prerequisite for autoimmune disease development in genetically susceptible individuals. Note: this remains a hypothesis for conditions beyond celiac, not an established causal chain.
Several factors have genuine mechanistic evidence for disrupting tight junctions or damaging the epithelium. These are not equivalent in their effect size — acute sepsis and a glass of wine operate on very different scales.
NSAIDs (non-steroidal anti-inflammatory drugs) are among the best-documented causes of increased intestinal permeability. Aspirin, ibuprofen, naproxen, and indomethacin inhibit COX enzymes → reduce prostaglandin synthesis → impair mucosal blood flow and mucus production → allow acid and bile to damage the epithelium. Bjarnason et al. demonstrated significant increases in lactulose:mannitol ratios in healthy volunteers taking NSAIDs short-term. Chronic NSAID use is associated with NSAID enteropathy — a diffuse small intestinal injury distinct from gastric ulcers.
PPIs (proton pump inhibitors) alter the upper GI environment, and some evidence suggests they disrupt the small intestinal microbiome, potentially affecting barrier function through dysbiosis. The direct effect on tight junctions is less well-characterized than NSAIDs.
Alcohol is a direct intestinal toxin. Ethanol and its metabolite acetaldehyde both disrupt tight junction proteins — acetaldehyde in particular causes redistribution of ZO-1 and occludin from the junctional complex into the cytoplasm. Chronic alcohol use produces a well-documented increase in intestinal permeability that contributes to alcoholic liver disease via portal LPS translocation.
Dysbiosis — microbial imbalance — can both cause and result from increased permeability, creating a self-reinforcing cycle. Pathobionts such as Proteobacteria overgrowth release LPS and other bacterial products that directly activate innate immune pathways and degrade tight junctions. Loss of keystone species like Faecalibacterium prausnitzii and Akkermansia muciniphila reduces butyrate production and mucus layer integrity respectively.
Low-fiber diet reduces short-chain fatty acid (SCFA) production — particularly butyrate, the primary energy source for colonocytes. Butyrate promotes tight junction assembly by inhibiting HDAC (histone deacetylase) enzymes and upregulating claudin expression. Rodent studies consistently show that fiber deprivation thins the mucus layer and increases colonic permeability.
Psychological stress acts through the gut-brain axis. Corticotropin-releasing hormone (CRH) released during stress activates mast cells in the gut mucosa, which release proteases and histamine that degrade tight junctions. This is likely relevant to IBS, where psychological stress reliably worsens symptoms and barrier function markers.
Antibiotics transiently increase intestinal permeability, likely through dysbiosis-mediated reduction in SCFA production and disruption of colonization resistance. The effect is typically reversible as the microbiome recovers, though recovery timelines vary considerably between individuals.
This is where the science requires careful reading. Elevated markers of intestinal permeability have been found in many conditions — but association is not causation, and in many cases it is unclear whether permeability is driving disease or whether disease-related inflammation is disrupting the barrier.
| Condition | Permeability Evidence | Causal Role? |
|---|---|---|
| Celiac Disease | Robust — multiple studies, normalization on GFD | Yes — mechanistically established |
| Crohn's Disease | Strong — increased permeability precedes flares in some studies; seen in first-degree relatives | Probable contributing factor; may be bidirectional |
| Ulcerative Colitis | Present during active disease; partially reverses in remission | Likely consequence more than cause |
| IBS | Elevated in post-infectious IBS and IBS-D subtype; mast cell activation shown | Uncertain; may be a subset phenomenon |
| Type 1 Diabetes | Shown in NOD mouse models; some human studies in children pre-onset | Animal model support; human causality unconfirmed |
| Non-Alcoholic Fatty Liver (NAFLD) | Consistent — portal LPS elevations correlate with disease severity | Likely contributing; LPS → hepatic TLR4 activation is plausible mechanism |
| Sepsis | Dramatic — gut is a primary driver of systemic bacterial translocation in critical illness | Yes — well-established in critical care medicine |
| Autism, Depression, Chronic Fatigue | Some studies report elevated zonulin or LPS-binding protein | Not established; confounding is high; do not self-diagnose based on these claims |
The "leaky gut causes everything" framework has outpaced the evidence. Fasano's hypothesis — that increased intestinal permeability is a necessary precondition for autoimmune disease — is scientifically plausible and generates useful research questions. It is not, however, confirmed for most conditions it is applied to in wellness contexts. Correlation between elevated zonulin and a disease does not mean zonulin-mediated permeability caused the disease. Many inflammatory diseases will secondarily disrupt the gut barrier. Treating every chronic symptom as "leaky gut" without appropriate diagnosis delays proper medical evaluation.
Several tests are available, but their clinical utility and reliability differ considerably. Here is a clear-eyed assessment of each.
The most validated research method for measuring small intestinal permeability. The patient drinks a solution containing lactulose (a large disaccharide that should not be absorbed under normal conditions) and mannitol (a small monosaccharide that is absorbed transcellularly). Urine is collected for several hours and both sugars are measured. A high lactulose:mannitol ratio indicates increased paracellular permeability — too much lactulose is getting through the tight junctions.
This test is the most mechanistically direct measure of intestinal permeability available. Its limitations: it only reflects small intestinal permeability, not colonic; it requires timed urine collection; test-to-test variability is significant; and "normal" ranges vary between labs. It is primarily a research tool and not widely available as a clinical diagnostic.
Offered commercially by companies including Cyrex Laboratories (Array 2: Intestinal Antigenic Permeability Screen) and others. The premise: elevated serum zonulin reflects active tight junction opening.
Reliability caveats are significant. Multiple systematic reviews have questioned the analytical validity of commercial ELISA assays marketed as measuring zonulin — many cross-react with other complement proteins and do not specifically measure what they claim. Vanuytsel et al. (2017) found that commonly used zonulin ELISAs detect a range of related proteins, not just zonulin itself. Intra-individual variability is high. Moderate reliability for population-level research; lower reliability for individual clinical decision-making.
I-FABP is a protein released by enterocytes when they are damaged — it appears in blood and urine as a marker of acute epithelial injury. It is a better marker of enterocyte death than of tight junction permeability per se. It is clinically used in critical care settings to detect gut ischemia and has research applications in conditions like celiac disease and radiation enteritis. Not yet a routine clinical test for outpatient "leaky gut" evaluation.
Do not make major health decisions based on a single direct-to-consumer zonulin test result. The analytical limitations of these assays are well-documented in the literature. A positive result does not confirm "leaky gut syndrome." A negative result does not rule out intestinal permeability issues. If you have symptoms suggesting celiac disease, IBD, or another condition with known permeability involvement, the appropriate next step is evaluation by a gastroenterologist — not interpretation of a mail-order zonulin panel. The lactulose:mannitol test, performed through an academic gastroenterology center, is more meaningful if permeability assessment is clinically warranted.
The research base here is mixed. Some interventions have solid human evidence; others have strong mechanistic rationale but limited controlled human data. We present each honestly.
Evidence level: Moderate — human RCT data exists. Zinc carnosine is a chelated compound of zinc and L-carnosine that is mucoprotective in the gut. Unlike free zinc, the chelated form remains intact through the stomach and delivers both zinc (essential cofactor for epithelial repair) and carnosine (free radical scavenger) directly to the intestinal mucosa.
The landmark study: Mahmood et al. (2007), published in Alimentary Pharmacology & Therapeutics, demonstrated in a double-blind RCT that zinc carnosine supplementation in healthy volunteers significantly reduced NSAID-induced small intestinal permeability (measured by lactulose:mannitol ratio) and enterocyte damage (measured by I-FABP). This is one of the cleaner human studies in this space — it used an objective permeability measure and had a clear, controlled mechanism of injury.
Additional evidence suggests zinc carnosine may enhance claudin-3 expression and accelerate gastric mucosal healing. It is widely used in Japan as an approved treatment for gastric ulcers (Polaprezinc). Typical dose studied: 75 mg twice daily.
View Zinc Carnosine on Amazon →Affiliate link — we earn a small commission at no cost to you. This supports GutCode's research coverage.
Evidence level: Moderate for critical care; limited for outpatient IBS/permeability. Glutamine is the most abundant free amino acid in the body and is the primary fuel source for rapidly dividing cells — including enterocytes and colonocytes. Under physiological stress (surgery, critical illness, intense exercise), glutamine becomes conditionally essential, and the intestinal epithelium is particularly vulnerable to depletion.
The strongest evidence is in clinical settings: Sevastiadou et al. (2011) in a neonatal ICU context showed glutamine supplementation reduced NEC (necrotizing enterocolitis) incidence and intestinal permeability markers. Multiple critical care trials support glutamine's role in maintaining gut barrier integrity during sepsis and after major surgery. For healthy adults or outpatient IBS management, the evidence is more limited — a few small trials suggest improvement in permeability markers and symptom scores, but rigorous large RCTs are lacking.
Mechanistically, glutamine promotes tight junction protein expression (including claudin-1 and occludin), supports mucus production, and fuels enterocyte proliferation. It is safe at doses studied (5–15g/day) and represents a reasonable supplement for individuals with known risk factors for permeability — NSAID users, competitive athletes, those in post-antibiotic recovery.
View L-Glutamine Powder on Amazon →Affiliate link — we earn a small commission at no cost to you. This supports GutCode's research coverage.
Evidence level: Emerging — first-in-human studies promising. A. muciniphila is a gram-negative mucin-degrading bacterium that constitutes 1–4% of the fecal microbiota in healthy individuals and is consistently reduced in obesity, T2D, IBD, and numerous other conditions associated with barrier dysfunction. Its role in gut barrier maintenance is paradoxical: it degrades mucin as its primary carbon source, yet stimulates goblet cells to produce more mucin in response — net result is mucus layer renewal and thickening.
The outer membrane protein Amuc_1100 from A. muciniphila activates TLR2 signaling and directly enhances tight junction assembly. Plovier et al. (2017) in Nature Medicine demonstrated that pasteurized A. muciniphila improved metabolic parameters and gut barrier function in mice, and that Amuc_1100 alone was sufficient. Depommier et al. (2019) published the first human RCT — pasteurized A. muciniphila supplementation for 3 months improved insulin sensitivity and reduced LPS-binding protein compared to placebo in overweight/obese adults. Gut barrier effects were secondary endpoints but trended in the expected direction.
Evidence level: Theoretical with very limited direct evidence. Collagen is rich in glycine and proline. Glycine is a key fuel for colonocytes, an inhibitory neurotransmitter in the enteric nervous system, and has anti-inflammatory properties in vitro. The hypothesis is that supplemental collagen peptides provide glycine and other amino acids that support epithelial repair. There are no rigorous human RCTs specifically measuring intestinal permeability as a primary outcome for collagen supplementation. Bone broth contains similar amino acids at much lower concentrations and in highly variable amounts depending on preparation — it is unlikely to provide therapeutic doses, though it may contribute as part of a broader anti-inflammatory diet.
Consult your physician before starting any supplement protocol, particularly if you have a diagnosed GI condition or are on prescription medications. This is an educational framework, not medical advice.
Intestinal permeability is a real, measurable biological phenomenon. The tight junction complex is a regulated barrier, not a static seal, and many factors — from NSAIDs to alcohol to dysbiosis to psychological stress — can meaningfully disrupt it. In celiac disease and Crohn's disease, the permeability disruption is causally important. In sepsis, gut barrier failure can be life-threatening.
But "leaky gut" as a catch-all explanation for chronic illness is not supported by the current evidence base. The zonulin hypothesis is scientifically valuable and worth continued research. It is not a confirmed mechanism for most of the conditions it is popularly attributed to. Consumer zonulin tests have significant analytical limitations. Self-diagnosing "leaky gut" and pursuing unproven treatments can delay proper medical evaluation for conditions that have specific, effective treatments.
The interventions with the best human evidence — zinc carnosine, removal of NSAIDs and alcohol, high-diversity fiber intake, fermented foods — are low-risk and broadly beneficial regardless of your intestinal permeability status. That is the space where it is reasonable to act without waiting for definitive proof. Everything else is mechanistically plausible but should be held with appropriate scientific uncertainty.